The STING agonist 2′,3′-cGAMP has been shown to activate the cGAS-STING-IRF3 pathway and modify the tumor immune microenvironment in the treatment of solid tumors (triple-negative breast cancer (TNBC) cells). Here, STING1 is linked to neoplasm.